<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04053647</url>
  </required_header>
  <id_info>
    <org_study_id>RC19_0021</org_study_id>
    <nct_id>NCT04053647</nct_id>
  </id_info>
  <brief_title>Quality of Life Evaluation (SF-36) in Patients With Permanent Hypoparathyroidism After Total Thyroidectomy (Qol-Hypopara)</brief_title>
  <official_title>Quality of Life Evaluation (SF-36) in Patients With Permanent Hypoparathyroidism After Total Thyroidectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier le Mans</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nancy University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pitié-Salpêtrière Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Persistent hypoparathyroidism is an underestimate but major complication of total
      thyroidectomy. The hypothesis of the investigators is that the mental health is impaired in
      hypoparathyroid patients compared with thyroidectomized patients without hypoparathyroidism.
      The investigators evaluated the quality of life using the SF-36 survey in comparison with a
      control population of patients thyroidectomized but free from this complication. The voice
      quality, the cardiovascular risk, the kidney function and the incidence of urinary lithiasis
      were also evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Persistent hypoparathyroidism is an underestimate but major complication of total
      thyroidectomy. In this retrospective, observational, multicentre study, the investigators
      evaluated the quality of life using the SF-36 survey in comparison with a control population
      of patients thyroidectomized but free from this complication. Patients in six centers in
      France (Angers, Le Mans, Limoges, Nancy, Nantes, la Pitié-Salpétrière) and in the association
      &quot;Hypoparathyroïdisme France&quot; were contacted by mail. The primary endpoint was the mental
      health. The physic and global quality of life scores were assessed as secondary endpoints.
      Medical and VHI surveys were also send to the patients. The voice quality, the cardiovascular
      risk, the kidney function and the incidence of urinary lithiasis were also evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 30, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mental health</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Items from mental quality of life score defined by the SF36 (Short Form 36) survey</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physical quality score</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Items from the SF36 (Short Form 36) survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global quality of life score</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Items from the SF36 (Short Form 36) survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Voice quality</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Items from the VHI (Voice Handicap Index) survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function quality</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Serum creatinine and clearance dosage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of urinary lithiasis</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Serum creatinine and clearance dosage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of cardiovascular complications</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Defined as ischemic cardiopathy</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Hypoparathyroidism</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Hypoparathyroid patients</arm_group_label>
    <description>Patients with persistent hypoparathyroidism after total thyroidectomy, defined as serum PTH inferior to 15 pg/mL 6 months after surgery and the need of vitamin-calcic supplementation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control patients, without hypoparathyroidism</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-interventional study</intervention_name>
    <description>Non-interventional study</description>
    <arm_group_label>Control patients, without hypoparathyroidism</arm_group_label>
    <arm_group_label>Hypoparathyroid patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population is that of hypoparathyroid patients of the Hypoparathyroidism France
        combination who have undergone total thyroidectomy and who have agreed to participate in
        the study.

        Patients with permanent hypoparathyroidism who were included in the ThyrQol study and in
        the FOTHYR study will also be solicited. Endocrinologists at the University Hospital of
        Nantes also have patients with permanent hypoparathyroidism in their patients.

        The control population consists of patients who had a total thyroidectomy and were included
        in the ThyrQol study between 2014 and 2018, without sequelary hypoparathyroidism.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients operated of total thyroidectomy

          -  Patients suffering from persistent hypoparathyroidism defined as serum PTH inferior to
             15 pg/mL 6 months after the surgery, requiring vitamin-calcic supplementation.

          -  Age superior to 18

          -  Answering the survey

        Exclusion Criteria:

          -  Pregnancy at the time of the study

          -  Age inferior to 18 or adult under guardianship

          -  Patients with vitamino-calcic supplementation without serum PTH measurement

          -  Cause of hypoparathyroidism other than post-operatory.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eric MIRALLIE, PU-PH</last_name>
    <phone>0240083166</phone>
    <email>eric.mirallie@chu-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cécile CAILLARD, PH</last_name>
    <phone>0240087826</phone>
    <email>cecile.caillard@chu-nantes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine HAMY, PU-PH</last_name>
      <phone>0241353618</phone>
      <email>anhamy@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Le Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henri-Pierre DERNIS</last_name>
      <phone>0243432430</phone>
      <email>phdernis@ch-lemans.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muriel MATHONNET, PU-PH</last_name>
      <phone>0555056701</phone>
      <email>mathonnet@unilim.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent BRUNAUD, PU-PH</last_name>
      <phone>0383153120</phone>
      <email>l.brunaud@chu-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric MIRALLIE, PU-PH</last_name>
      <phone>0240083166</phone>
      <email>eric.mirallie@chu-nantes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Cécile CAILLARD, PH</last_name>
      <phone>0240087826</phone>
      <email>cecile.caillard@chu-nantes.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Delphine DRUI, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maëlle LE BRAS, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP La Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice MENEGAUX, PU-PH</last_name>
      <email>fabrice.menegaux@psl.aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Christophe TRASALLET, PU-PH</last_name>
      <email>christophe.tresallet@psl.aphp.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 22, 2019</study_first_submitted>
  <study_first_submitted_qc>August 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2019</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoparathyroidism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

